Pharmaceutical Technology Center Guides RuiCai Biotech in Developing High-Value Liposomal Drug for Kidney Disease


In the fourth quarter of 2024, Rilong Fine Chemicals—a company specializing in liposomes and cosmetic raw materials—and Ruicai Biotechnology—a firm focused on developing drugs for kidney diseases in humans and pets—visited Nippon Fine Chemical’s Takasago production plant and Osaka headquarters. The visit was part of preparations for the Chemistry, Manufacturing, and Controls (CMC) requirements necessary for an Investigational New Drug (IND) application.

Rilong Fine Chemicals notes that high-value pharmaceutical products—such as generics targeting international niche markets and those developed via the 505(b)(2) regulatory pathway—represent a key development trend in Taiwan’s current biotech and pharmaceutical industry. Through the promotion of its nanolipid carrier technology—a topic highlighted at its seminars on liposomes—Rilong Fine Chemicals has, in recent years, established strategic partnerships with several innovative drug-development startups, including Ruicai Biotechnology.


With its drug repositioning platform—focused on new indications and novel dosage forms—as its core technology, RuiCai Biotech develops liposomal drugs by repurposing existing medications. The company currently holds 14 patents and has established a strategic presence in key healthcare markets, including Japan, the United States, and the European Union.


With guidance from the Center for Drug Evaluation (CDE), Ruicai Biotech was selected for subsidies under the Ministry of Economic Affairs’ Industrial Development Administration—specifically through the 2018 "Niche Drug Development and Enhancement Program" and the 2019 "Pharmaceutical Industry Technical Guidance and Promotion Program"—to optimize its drug dosage forms. Furthermore, the company was referred to Rilong Fine Chemicals, which was subsequently commissioned to conduct research on the standardization of the drug’s specifications.


Meanwhile, Ruicai Biotech has adopted a "hub-and-spoke" R&D model, engaging in industry-academia collaborations: the laboratory of Professor Yu-Tse Wu at Kaohsiung Medical University is tasked with analyzing the physicochemical properties of formulations and batches; the laboratory of Professor Feng-Yen Lin at Taipei Medical University is conducting preclinical efficacy studies; and the Development Center for Biotechnology (DCB) has been commissioned to carry out pilot studies on drug stability.


In the second quarter of 2024, Rich-Life Biotech transitioned its liposome preparation process from a laboratory scale to a pilot-plant scale (liter/kilogram level). Key physicochemical parameters—such as particle size, drug content, and encapsulation efficiency—all met the targeted specifications. Consequently, facilitated by Jilong Fine Chemical, the company visited Nippon Fine Chemical’s Takasago production plant and its Osaka headquarters during the fourth quarter.


Established in 2009, Rilong Fine Chemicals is the only wholly-owned subsidiary of Nippon Fine Chemical Co., Ltd. in Taiwan. Its operations—encompassing the import, trade, and sales of raw materials and products—focus on liposomes and cosmetic ingredients. Furthermore, as of 2023, the company has expanded into the B2B2C sector for health supplement ingredients.


The company’s portfolio of best-selling cosmetic ingredients includes products manufactured by Nippon Fine Chemical—such as lanolin, amino acid-based sterol esters, high-efficiency penetration enhancers, high-performance functional emulsifiers, and cosmetic-grade cholesterol—as well as the exclusive hair-care product "Hair Iron" (Fa Tang Dou). Additionally, the company serves as an agent for cosmetic ingredient brands from Shanghai Huiwen Biotechnology.


We provide specialized services for liposome raw materials. Beyond supplying high-purity phospholipids and cholesterol—manufactured under cGMP standards and supported by Drug Master Files (DMF)—we also offer contract lipid synthesis, as well as services for the development of drug carriers and encapsulation research for novel liposomal therapeutics.


Since 2019, Rilong Fine Chemicals has regularly hosted the "Taiwan International Liposome Symposium," bringing together experts from Taiwan and Japan, as well as industry professionals, to foster exchange among academia, research, and the private sector, and to promote the commercial application of liposome technology.


 
— Share —